يعرض 1 - 10 نتائج من 42 نتيجة بحث عن '"Haberbosch, Isabella"', وقت الاستعلام: 1.94s تنقيح النتائج
  1. 1
    تقرير
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
  5. 5
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: https://orca.cardiff.ac.uk/id/eprint/136955/8/Mian2021_Article_CrizotinibActsAsABL1InhibitorC.pdfTest; Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia https://orca.cardiff.ac.uk/view/cardiffauthors/A2186592A.htmlTest orcid:0000-0003-3758-1892 orcid:0000-0003-3758-1892, Ottmann, Oliver https://orca.cardiff.ac.uk/view/cardiffauthors/A2177092Z.htmlTest orcid:0000-0001-9559-1330 orcid:0000-0001-9559-1330, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin https://orca.cardiff.ac.uk/view/cardiffauthors/A2186591C.htmlTest orcid:0000-0003-1021-3811 orcid:0000-0003-1021-3811 and Mahajna, Jamal 2021. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K. Annals of Hematology 100 , pp. 2023-2029. 10.1007/s00277-020-04357-z https://doi.org/10.1007/s00277-020-04357-zTest file https://orca.cardiff.ac.uk/id/eprint/136955/8/Mian2021_Article_CrizotinibActsAsABL1InhibitorC.pdfTest

  6. 6
    دورية أكاديمية
  7. 7
  8. 8
    دورية أكاديمية

    المصدر: Liebers, Nora; Roider, Tobias; Bohn, Jan-Paul; Haberbosch, Isabella; Pircher, Andreas; Ferstl, Barbara; Ebnöther, Monika; Wendtner, Clemens-Martin; Dearden, Claire; Follows, George A; Ho, Anthony D; Müller-Tidow, Carsten; Dreger, Peter; Troussard, Xavier; Zenz, Thorsten; Dietrich, Sascha (2020). BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia, 34(5):1454-1457.

    وصف الملف: application/pdf

    العلاقة: https://www.zora.uzh.ch/id/eprint/180155/1/s41375-019-0646-y.pdfTest; info:pmid/31740808; urn:issn:0887-6924

  9. 9
  10. 10